# The Safety and Efficacy of Thermal Ablation Combined With Apatinib and Carilimub for Advanced Liver Cancer

> **NCT04204577** · PHASE2 · UNKNOWN · sponsor: **Chinese PLA General Hospital** · enrollment: 90 (estimated)

## Conditions studied

- BCLC Stage B Hepatocellular Carcinoma
- BCLC Stage C Hepatocellular Carcinoma

## Interventions

- **DRUG:** Apatinib Mesylate

## Key facts

- **NCT ID:** NCT04204577
- **Lead sponsor:** Chinese PLA General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-11-01
- **Primary completion:** 2021-11
- **Final completion:** 2023-11
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2019-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04204577

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04204577, "The Safety and Efficacy of Thermal Ablation Combined With Apatinib and Carilimub for Advanced Liver Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04204577. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*